Hiromichi Ebi
Overview
Explore the profile of Hiromichi Ebi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
3452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka N, Ebi H
Cancer Sci
. 2024 Dec;
116(3):600-612.
PMID: 39726416
KRAS was long deemed undruggable until the discovery of the switch-II pocket facilitated the development of specific KRAS inhibitors. Despite their introduction into clinical practice, resistance mechanisms can limit their...
2.
Kimura R, Adachi Y, Hirade K, Kisoda S, Yanase S, Shibata N, et al.
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456595
Background/objectives: Although tyrosine kinase inhibitors (TKIs) targeting EGFR-activating mutations significantly improved the outcome of EGFR-mutant NSCLC, resistance inevitably emerges. Despite the heterogeneity of these resistance mechanisms, many induce activation of...
3.
Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al.
Nat Med
. 2024 Sep;
30(11):3272-3283.
PMID: 39284954
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy...
4.
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, et al.
Clin Cancer Res
. 2024 Aug;
30(18):4167-4178.
PMID: 39163021
Purpose: HER2-targeted therapies in ERBB2-amplified metastatic colorectal cancer (mCRC) are effective; however, a notable portion of patients do not respond to treatment, and secondary resistance occurs in most patients receiving...
5.
Kitai H, Choi P, Yang Y, Boyer J, Whaley A, Pancholi P, et al.
Nat Commun
. 2024 Jul;
15(1):6076.
PMID: 39025835
Current KRAS (OFF) inhibitors that target inactive GDP-bound KRAS cause responses in less than half of patients and these responses are not durable. A class of RAS (ON) inhibitors that...
6.
Kitai H, Ebi H
Transl Lung Cancer Res
. 2024 Apr;
13(3):684-688.
PMID: 38601453
No abstract available.
7.
Bando H, Yamaguchi K, Mitani S, Sawada K, Mishima S, Komine K, et al.
Cancer Sci
. 2024 Jan;
115(3):1014-1021.
PMID: 38263580
Molecular testing to determine optimal therapies is essential for managing patients with colorectal cancer (CRC). In October 2022, the Japanese Society of Medical Oncology published the 5th edition of the...
8.
Lai X, Lui S, Lam H, Adachi Y, Sim W, Vasilevski N, et al.
NPJ Precis Oncol
. 2023 Dec;
7(1):136.
PMID: 38102334
Despite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely...
9.
Matsubara J, Mukai K, Kondo T, Yoshioka M, Kage H, Oda K, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2323336.
PMID: 37459099
Importance: Precision oncology using comprehensive genomic profiling (CGP) by next-generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical utility of CGP before the standard of care (SOC)...
10.
Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N, et al.
Nat Cancer
. 2023 Jun;
4(6):829-843.
PMID: 37277529
Tumor cells evade targeted drugs by rewiring their genetic and epigenetic networks. Here, we identified that inhibition of MAPK signaling rapidly induces an epithelial-to-mesenchymal transition program by promoting re-localization of...